PFE - Here's Why Mylan Fell 26.6% in 2019
Shares of Mylan (NASDAQ: MYL) fell over 26% last year, according to data provided by S&P Global Market Intelligence. The generic drug manufacturer struggled to overcome its negative association in the national discussion related to drug pricing practices and became embroiled in an industrywide price-fixing lawsuit brought by 44 state attorneys general.
The performance of the pharma stock looks even worse when considering that the S&P 500 delivered a 28.8% gain in 2019. Can plans to combine with Upjohn, the generic drug division of Pfizer (NYSE: PFE), provide relief to shareholders in 2020?
Image source: Getty Images.